Thymidine concentrations in serum and urine of different animal species and man.

Citations

1. Petraitis V, Petraitiene R, Kavaliauskas P, Naing E, Garcia A, Georgiades BN, Echols R, Bonomo RA, Yamano Y, Satlin MJ, Walsh TJ. Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.. Antimicrob Agents Chemother 2022 Oct 18;66(10):e0061822.
   doi: 10.1128/aac.00618-22pubmed: 36154614google scholar: lookup
2. Lasko MJ, Gethers ML, Tabor-Rennie JL, Nicolau DP, Kuti JL. In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth.. Antimicrob Agents Chemother 2022 Mar 15;66(3):e0216721.
   doi: 10.1128/aac.02167-21pubmed: 35007135google scholar: lookup
3. Liang K, Abt ER, Le TM, Cho A, Dann AM, Cui J, Li L, Rashid K, Creech AL, Wei L, Ghukasyan R, Rosser EW, Wu N, Carlucci G, Czernin J, Donahue TR, Radu CG. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [(18)F]FLT PET imaging.. Proc Natl Acad Sci U S A 2021 Sep 7;118(36).
   doi: 10.1073/pnas.2105390118pubmed: 34480004google scholar: lookup
4. Nakamura R, Oota M, Matsumoto S, Sato T, Yamano Y. In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia.. Antimicrob Agents Chemother 2021 Mar 18;65(4).
   doi: 10.1128/AAC.01436-20pubmed: 33526491google scholar: lookup
5. Chen IH, Kidd JM, Abdelraouf K, Nicolau DP. Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.. Antimicrob Agents Chemother 2019 Sep 9;63(12).
   doi: 10.1128/AAC.01558-19pubmed: 31591126google scholar: lookup
6. Huang DB, Park JH, Murphy TM. Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model.. Eur J Clin Microbiol Infect Dis 2019 Feb;38(2):409-412.
   doi: 10.1007/s10096-018-3440-2pubmed: 30483998google scholar: lookup
7. Park JH, Craig W, Marchillo K, Huang DB, Andes DR. Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.. Antimicrob Agents Chemother 2018 Apr;62(4).
   doi: 10.1128/AAC.02550-17pubmed: 29378717google scholar: lookup
8. Connolly J, Boldock E, Prince LR, Renshaw SA, Whyte MK, Foster SJ. Identification of Staphylococcus aureus Factors Required for Pathogenicity and Growth in Human Blood.. Infect Immun 2017 Nov;85(11).
   doi: 10.1128/IAI.00337-17pubmed: 28808156google scholar: lookup
9. Wiehr S, Rolle AM, Warnke P, Kohlhofer U, Quintanilla-Martinez L, Reischl G, Autenrieth IB, Pichler BJ, Autenrieth SE. The Positron Emission Tomography Tracer 3'-Deoxy-3'-[18F]Fluorothymidine ([18F]FLT) Is Not Suitable to Detect Tissue Proliferation Induced by Systemic Yersinia enterocolitica Infection in Mice.. PLoS One 2016;11(10):e0164163.
   doi: 10.1371/journal.pone.0164163pubmed: 27701464google scholar: lookup
10. Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.. Proc Natl Acad Sci U S A 2016 Apr 12;113(15):4027-32.
    doi: 10.1073/pnas.1524212113pubmed: 27035974google scholar: lookup
11. Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin AB, Dickgreber N, Wehler T, Sebastian M. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.. Invest New Drugs 2014 Oct;32(5):955-68.
    doi: 10.1007/s10637-014-0114-5pubmed: 24942404google scholar: lookup
12. Lee SJ, Yeo JS, Lee HJ, Lee EJ, Kim SY, Jang SJ, Lee JJ, Ryu JS, Moon DH. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.. Eur J Nucl Med Mol Imaging 2014 Jul;41(7):1327-35.
    doi: 10.1007/s00259-014-2712-zpubmed: 24562648google scholar: lookup
13. Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.. J Biol Chem 2012 Jan 2;287(1):446-454.
    doi: 10.1074/jbc.M111.314666pubmed: 22074768google scholar: lookup
14. Humphries RM, Lee C, Hindler JA. Aerococcus urinae and trimethoprim-sulfamethoxazole.. J Clin Microbiol 2011 Nov;49(11):3934-5.
    doi: 10.1128/JCM.05535-11pubmed: 21918023google scholar: lookup
15. Nair-Gill E, Wiltzius SM, Wei XX, Cheng D, Riedinger M, Radu CG, Witte ON. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice.. J Clin Invest 2010 Jun;120(6):2005-15.
    doi: 10.1172/JCI41250pubmed: 20484820google scholar: lookup
16. Zander J, Besier S, Ackermann H, Wichelhaus TA. Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs.. Antimicrob Agents Chemother 2010 Mar;54(3):1226-31.
    doi: 10.1128/AAC.00705-09pubmed: 20028816google scholar: lookup
17. Entenza JM, Haldimann A, Giddey M, Lociuro S, Hawser S, Moreillon P. Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.. Antimicrob Agents Chemother 2009 Sep;53(9):3635-41.
    doi: 10.1128/AAC.00325-09pubmed: 19564362google scholar: lookup
18. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD. Tuberculosis and trimethoprim-sulfamethoxazole.. Antimicrob Agents Chemother 2009 Nov;53(11):4789-93.
    doi: 10.1128/AAC.01658-08pubmed: 19564358google scholar: lookup
19. Barth RF, Yang W, Wu G, Swindall M, Byun Y, Narayanasamy S, Tjarks W, Tordoff K, Moeschberger ML, Eriksson S, Binns PJ, Riley KJ. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors.. Proc Natl Acad Sci U S A 2008 Nov 11;105(45):17493-7.
    doi: 10.1073/pnas.0809569105pubmed: 18981415google scholar: lookup
20. Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, Aibgirhio FI, Golovko O, Jackman AL, Aboagye EO. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.. Cancer Res 2008 May 15;68(10):3827-34.
    doi: 10.1158/0008-5472.CAN-08-0135pubmed: 18483267google scholar: lookup
21. Bradbury MS, Hambardzumyan D, Zanzonico PB, Schwartz J, Cai S, Burnazi EM, Longo V, Larson SM, Holland EC. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.. J Nucl Med 2008 Mar;49(3):422-9.
    doi: 10.2967/jnumed.107.047092pubmed: 18287265google scholar: lookup
22. Li KM, Rivory LP, Hoskins J, Sharma R, Clarke SJ. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.. Br J Clin Pharmacol 2007 Jan;63(1):67-74.
    doi: 10.1111/j.1365-2125.2006.02710.xpubmed: 16827816google scholar: lookup
23. Tseng JR, Dandekar M, Subbarayan M, Cheng Z, Park JM, Louie S, Gambhir SS. Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice.. J Nucl Med 2005 Nov;46(11):1851-7.
    pubmed: 16269599
24. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities.. Eur J Nucl Med Mol Imaging 2004 Dec;31(12):1659-72.
    doi: 10.1007/s00259-004-1687-6pubmed: 15565331google scholar: lookup
25. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography.. Eur J Nucl Med Mol Imaging 2004 Aug;31(8):1182-206.
    doi: 10.1007/s00259-004-1607-9pubmed: 15241631google scholar: lookup
26. Min JJ, Iyer M, Gambhir SS. Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection.. Eur J Nucl Med Mol Imaging 2003 Nov;30(11):1547-60.
    doi: 10.1007/s00259-003-1238-6pubmed: 14579096google scholar: lookup
27. Tokunaga T, Oka K, Takemoto A, Ohtsubo Y, Gotoh N, Nishino T. Efficacy of trimethoprim in murine experimental infection with a thymidine kinase-deficient mutant of Escherichia coli.. Antimicrob Agents Chemother 1997 May;41(5):1042-5.
    doi: 10.1128/AAC.41.5.1042pubmed: 9145866google scholar: lookup
28. Banks SD, Waters KA, Barrett LL, Dickerson S, Pendergast W, Smith GK. Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations.. Cancer Chemother Pharmacol 1994;33(6):455-9.
    doi: 10.1007/BF00686500pubmed: 8137455google scholar: lookup
29. Pressacco J, Wiley JS, Jamieson GP, Erlichman C, Hedley DW. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.. Br J Cancer 1995 Oct;72(4):939-42.
    doi: 10.1038/bjc.1995.437pubmed: 7547244google scholar: lookup
30. Daluge SM, Purifoy DJ, Savina PM, St Clair MH, Parry NR, Dev IK, Novak P, Ayers KM, Reardon JE, Roberts GB. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.. Antimicrob Agents Chemother 1994 Jul;38(7):1590-603.
    doi: 10.1128/AAC.38.7.1590pubmed: 7526782google scholar: lookup
31. Eells JT, Spector R. Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma.. Neurochem Res 1983 Nov;8(11):1451-7.
    doi: 10.1007/BF00965000pubmed: 6656991google scholar: lookup
32. Eells JT, Spector R. Determination of ribonucleosides, deoxyribonucleosides, and purine and pyrimidine bases in adult rabbit cerebrospinal fluid and plasma.. Neurochem Res 1983 Oct;8(10):1307-20.
    doi: 10.1007/BF00964000pubmed: 6656989google scholar: lookup
33. King CH, Shlaes DM, Dul MJ. Infection caused by thymidine-requiring, trimethoprim-resistant bacteria.. J Clin Microbiol 1983 Jul;18(1):79-83.
    doi: 10.1128/jcm.18.1.79-83.1983pubmed: 6604070google scholar: lookup
34. Wingard JR, Stuart RK, Saral R, Burns WH. Activity of trifluorothymidine against cytomegalovirus.. Antimicrob Agents Chemother 1981 Sep;20(3):286-90.
    doi: 10.1128/AAC.20.3.286pubmed: 6272627google scholar: lookup
35. Jones C, Stevens DL, Ojo O. Effect of minimal amounts of thymidine on activity of trimethoprim-sulfamethoxazole against Staphylococcus epidermidis.. Antimicrob Agents Chemother 1987 Feb;31(2):144-7.
    doi: 10.1128/AAC.31.2.144pubmed: 3494425google scholar: lookup
36. Walzer PD, Foy J, Steele P, Kim CK, White M, Klein RS, Otter BA, Allegra C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.. Antimicrob Agents Chemother 1992 Sep;36(9):1935-42.
    doi: 10.1128/AAC.36.9.1935pubmed: 1416884google scholar: lookup
37. Sugimoto Y, Ohe Y, Nishio K, Ohmori T, Morikage T, Fujiwara Y, Saijo N. Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.. Br J Cancer 1992 Jun;65(6):857-64.
    doi: 10.1038/bjc.1992.181pubmed: 1319727google scholar: lookup
38. Goldstein BP, Ripamonti IF, Bolzoni G, Carniti G, Arioli V. Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro.. Antimicrob Agents Chemother 1979 Dec;16(6):736-42.
    doi: 10.1128/AAC.16.6.736pubmed: 533255google scholar: lookup